RecruitingPhase 2Phase 3NCT06789783

Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment


Sponsor

University of Milan

Enrollment

34 participants

Start Date

May 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The study "Cornelia de Lange Syndrome: assessing positive effects of Lithium treatment - CLoSER" aims to evaluate the effectiveness on behavioral modifications of lithium carbonate therapy in patients with Cornelia de Lange syndrome (CdLS). CdLS is a rare genetic disease caused by autosomal mutations dominant or X-linked. The prevalence of CdLS is estimated to be between 1:10,000-30,000 newborns, but it is probably underestimated because the most cases mild ones may go undiagnosed. This syndrome is characterized by slow growth before and after birth with intellectual disability and short stature, from major malformations such as facial anomalies, neurological disorders, gastrointestinal and musculoskeletal malformations. To date, for these patients only targeted medical and surgical therapeutic interventions are recommended for improving the quality of life. No drug therapy is validated for the cognitive/behavioral disorders. It has been shown that lihium-dependent activation of the WNT pathway is able to recover the Abnormal phenotype in many CdLS models. Lithium is already widely used in psychiatry and has a long history of clinical efficacy. Recently some studies are evaluating the effect of lithium in patients with characteristics common to CdLS showing promising results . This trial intends to transfer the preliminary data obtained from in vitro and in vivo studies on patients with CdLS. Given the currently untreatable nature of the syndrome, this treatment could represent a possible therapeutic strategy aimed at improving the behavioral and intellectual disabilities typical of CdLS.


Eligibility

Min Age: 4 Years

Inclusion Criteria7

  • Age > 4 years
  • Body weight within the normal range in the reference range for CdLS, based on age and height
  • Diagnosis of CdLS based on consensus clinical criteria and a confirmed mutation in the NIPBL gene
  • Stable drug regimen for 4 weeks prior to starting the study
  • Written consent signed by parent/legal guardian/representative prior to the screening visit
  • Ability to take the study drug provided in capsules or drops (for younger patients and those with swallowing difficulties) or combined with food/drinks
  • Caregiver must be able to understand the instructions and participate knowingly in the study

Exclusion Criteria4

  • The patient is participating in another clinical trial
  • QT interval prolongation, thyroid dysfunction, renal insufficiency, hepatic insufficiency, leukopenia, or other currently clinically significant medical disorders (as determined by the investigator), other than those directly related to CdLS
  • QTcF interval on ECG greater than 450 msec
  • Severe diabetes mellitus or inherited metabolic disorder

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLithium Carbonate Capsule

10mg/Kg twice a day, 150mg or 300mg Lithium Carbonate


Locations(1)

University of Milan

Milan, MI, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06789783


Related Trials